We are seeking funding for the IOTOD 2022 conference, if you are interested please contact [email protected].
The 2022 IOTOD conference is supported by the following companies:
Gold Sponsors
Camurus
Camurus is a Swedish research-based pharmaceutical company with more than 25 years of innovation and leadership in lipid-based drug delivery technologies. For the development of new product candidates, Camurus utilises its own patented FluidCrystal® drug delivery technologies. New proprietary medicines with improved properties and better treatment outcomes are developed by combining these technologies with established and regulatory approved active ingredients. Camurus’ development pipeline contains product candidates that address conditions with distinct and important medical needs, such as cancer, endocrine disorders, metabolic disorders, opioid dependence and chronic pain.
Silver Sponsors
Gilead
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Other Supporters
Accord Healthcare
Accord Healthcare is a dynamic pharmaceutical company, spanning both generics and speciality products, committed to addressing public health priorities. We are now bringing our expertise and patient-centric approach to address some of the ties related to addiction management.
At Accord Healthcare, we are sensitive to the diverse pasts and journeys of people living with addiction, as well as the related social stigmas, which can become barriers to recovery. We understand the challenges and complexities faced by the healthcare community in the support and treatment of patients with addiction
Molteni Farmaceutici
Molteni Farmaceutici is a privately held pharmaceutical company founded in 1892 with a strong knowledge and experience in opioids and a wide spectrum of pharmaceutical products for the treatment of pain and drug addiction.
Molteni Farmaceutici is committed to consolidate its international leadership, always focused on the main therapeutic areas, enlarging its geographies, to satisfy patients ‘needs and improve the standard of care.
With an eye to development and internationalization, Molteni Farmaceutici constantly pursues chemical-pharmaceutical, clinical and biomedical research to develop new drugs and improve therapeutic applications.
OUR VISION
Molteni Farmaceutici constantly focuses its attention on people and society, without losing sight of numbers and markets. A solid past behind it, the awareness of its own value and the ability to look to the future with determination, make the company an Italian, Tuscan, and Florentine excellence in the increasingly global drug market.
OUR MISSION
Molteni Farmaceutici at the centre of its work and commitment always puts the person, his health, and his quality of life. The company, aware and proud of its responsibility, continues to seek and pursue an ever higher therapeutic standard, with ongoing innovation and research.
Indivior
Indivior is a global pharmaceutical company working to change patients’ lives by developing medicines to treat addiction and serious mental illnesses.
The medications Indivior provides play an essential role in treating opioid use disorder and addressing the opioid crisis.
Patient needs inspire us.
At the heart of Indivior is an unwavering commitment to support the patient journey to treatment and recovery, enable access to effective treatment, and provide education, new scientific understanding, and knowledge to the treatment community.
From the beginning, we have worked hard to destigmatize opioid use disorder by advocating that opioid use disorder to be recognized as a treatable medical condition, and not a moral failing.
We have an unrivaled track record for developing innovative medicines to treat opioid addiction.
Our Vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.
